Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome

Table 3

Results of the treatment in two subgroups of women taking the same dose of ALA (800 mg) and two different doses of MI per day (group A 2000 mg; group B 1000 mg).

	Group A		Group B
	Baseline	6 months	Baseline	6 months
BMI (kg/m^2)	27.10 ± 4.19	25.02 ± 4.03	26.79 ± 6.43	27.15 ± 6.12.62
FSH (mIU/mL)	5.73 ± 1.85	4.88 ± 1.45	7.11 ± 3.23	5.26 ± 2.62
LH (mIU/mL)	14.73 ± 8.42	13.42 ± 6.32	12.09 ± 6.95	9.59 ± 6.80
Estradiol (pmol/L)	255.16 ± 219.14	402.01 ± 339.38	277.04 ± 290.22	415.38 ± 345.11
Total testosterone (ng/mL)	2.88 ± 0.73	2.70 ± 0.80	2.18 ± 0.55	2.18 ± 0.59
Fasting insulin (pmol/L)	66.81 ± 30.00	71.04 ± 29.17	61.60 ± 24.86	55.63 ± 20.21
HOMA-IR	1.93 ± 0.91	2.00 ± 0.84	1.79 ± 0.73	1.66 ± 0.64
AUC-insulin (pmol/L × 120 min)	60833.82 ± 19899.02	51441.04 ± 22941.46	52009.79 ± 38484.58	49054.10 ± 22024.79

The higher dose of MI caused changes in BMI, estradiol levels, and AUC-insulin, while the lowest dose caused changes in FSH, LH, and estradiol levels. All data are reported as the mean ± SD. vs. baseline of the same group; vs. baseline of the same group. ALA: α-lipoic acid; AUC: area under the curve; BMI: body mass index; FSH: follicle-stimulating hormone; HOMA-IR: homeostasis model assessment of insulin resistance; IR: insulin resistance; LH: luteinizing hormone; MI: myo-inositol; SD: standard deviation.